查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1708005

全球癌症诊断市场：产业分析、规模、份额、成长、趋势和预测（2025-2032）

Cancer Diagnostics Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025 - 2032
出版日期: | 出版商: Persistence Market Research | 英文 180 Pages | 商品交期: 2-5个工作天内

价格
简介目录

主要发现

  • 癌症诊断市场规模：1,378亿美元（2025年）
  • 预计市场价值：2,227亿美元（2032年）
  • 全球市场成长率：7.1%（2025年至2032年的复合年增长率）

癌症诊断市场 - 报告范围

癌症诊断涵盖了广泛的工具、技术和程序，旨在早期发现癌症，以改善治疗效果和存活率。该市场包括成像技术、切片检查技术、肿瘤生物标记、分子诊断和就地检验系统。这些诊断方法用于医院、病理实验室和专科诊所，以检测各种类型的癌症，包括乳癌、肺癌、结肠癌、前列腺癌、子宫颈癌和血癌。推动市场成长的因素是全球癌症发生率的上升、早期发现意识的提高以及精准诊断和个人化医疗的进步。

市场成长动力

全球癌症诊断市场受到多种因素的推动，尤其是由于人口老化、生活方式的改变和环境因素导致全球癌症发病率的增加。透过先进的诊断技术进行早期检测已显着提高了存活率，推动了对创新解决方案的需求。次世代定序(NGS)、液态切片和人工智慧成像等技术进步正在改变癌症检测并促进微创方法。政府支持癌症筛检计画的倡议、增加医疗保健支出以及肿瘤学伴同性诊断的日益普及正在进一步刺激市场扩张。

市场限制

儘管预计癌症诊断市场将经历强劲成长，但它仍面临多项挑战，包括高昂的诊断成本，尤其是先进的分子和基因组测试。中低收入国家诊断设施的有限性阻碍了早期发现和治疗。此外，癌症异质性和基因突变变化的复杂性需要不断创新和临床检验，从而增加开发成本和上市时间。监管障碍和报销限制也会影响新诊断技术的商业性可行性。应对这些挑战需要跨部门合作以及对经济实惠、可扩展的诊断平台的有针对性的投资。

市场机会

由于技术创新以及人工智慧和机器学习在诊断中的作用不断扩大，癌症诊断市场提供了巨大的成长机会。液态切片正在兴起，并逐渐被接受为一种非侵入性、即时癌症监测工具。对生物标记发现、巨量资料分析整合和多路復用诊断平台开发的投资不断增加，为个人化早期癌症诊断开闢了新的途径。此外，更加关注家庭癌症筛检工具和行动诊断可能会提高可近性和依从性，特别是在偏远和服务不足的地区。

该报告研究了全球癌症诊断市场，并对市场动态进行了详细分析，包括成长动力、趋势、机会和挑战。

目录

第一章执行摘要

第二章 市场概述

  • 市场范围和定义
  • 市场动态
    • 驱动程式
    • 限制因素
    • 机会
    • 任务
    • 主要趋势
  • COVID-19影响分析
  • 预测因子－相关性和影响力

第三章 增值考虑

  • 价值链分析
  • 诊断测试采用/利用率分析
  • 癌症盛行率和发生率
  • 政府在癌症诊断方面的措施和资金
  • 主要市场公司
  • 监管格局
  • PESTLE分析
  • 波特五力分析
  • 消费行为分析

第四章全球癌症诊断市场展望

  • 主要亮点
    • 市场规模及与前一年同期比较
    • 绝对的商机
  • 市场规模分析及预测
    • 市场规模表现分析（2019-2024）
    • 当前市场规模分析与预测（2025-2032）
  • 全球癌症诊断市场展望：诊断测试
    • 诊断测试市场规模表现分析（2019-2024）
    • 诊断测试的当前市场规模分析和预测（2025-2032）
    • 市场吸引力分析：诊断测试
  • 全球癌症诊断市场展望：形态学
    • 按类型分類的市场规模表现分析（2019-2024）
    • 目前市场规模分析及按类型预测（2025-2032）
    • 市场吸引力分析：形式
  • 全球癌症诊断市场展望：应用
    • 市场规模绩效分析：按应用（2019-2024）
    • 目前市场规模分析及应用预测（2025-2032）
    • 市场吸引力分析：应用
  • 全球癌症诊断市场展望：最终用途
    • 依最终用途分類的市场规模绩效分析（2019-2024 年）
    • 目前市场规模分析及最终用途预测（2025-2032）
    • 市场吸引力分析：最终用途

第五章全球癌症诊断市场展望区域

  • 市场规模绩效分析：按地区（2019-2024）
  • 目前市场规模分析及各地区预测（2025-2032）
    • 北美洲
    • 拉丁美洲
    • 欧洲
    • 东亚
    • 南亚和大洋洲
    • 中东和非洲
  • 市场吸引力分析：地区

6. 北美癌症诊断市场展望

7. 欧洲癌症诊断市场展望

第八章东亚癌症诊断市场展望

9. 南亚和大洋洲癌症诊断市场展望

第十章拉丁美洲癌症诊断市场展望

第 11 章中东和非洲癌症诊断市场展望

第十二章竞争格局

  • 市场占有率分析（2025年）
  • 市场结构
    • 竞争强度图：按市场
    • 竞争仪錶板
  • 公司简介（详情－概述、财务状况、策略、最新发展）
    • F. Hoffmann-La Roche Ltd
    • Thermo Fisher Scientific Inc.
    • Abbott Laboratories
    • Illumina Inc.
    • bioMerieux SA
    • Qiagen
    • Siemens Healthineers
    • GE Healthcare
    • Hologic Inc.
    • Agilent Technologies Inc.
    • Becton, Dickinson and Company (BD)
    • Myriad Genetics Inc.
    • AstraZeneca
    • Regeneron
    • Novartis
    • BIO-RAD LABORATORIES
    • CANCER DIAGNOSTICS INC.
    • QUIDEL CORPORATION
    • Koninklijke Philips NV (Philips)
    • 其他的

第十三章 附录

简介目录
Product Code: PMRREP35187

Persistence Market Research has recently released a comprehensive report on the worldwide market for cancer diagnostics. The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure. This research publication presents exclusive data and statistics outlining the anticipated growth trajectory of the global cancer diagnostics market from 2025 to 2032.

Key Insights:

  • Cancer Diagnostics Market Size (2025E): USD 137.8 Billion
  • Projected Market Value (2032F): USD 222.7 Billion
  • Global Market Growth Rate (CAGR 2025 to 2032): 7.1%

Cancer Diagnostics Market - Report Scope:

Cancer diagnostics encompass a wide range of tools, technologies, and procedures aimed at detecting cancer at early stages to improve treatment outcomes and survival rates. The market includes imaging technologies, biopsy techniques, tumor biomarkers, molecular diagnostics, and point-of-care testing systems. These diagnostics are utilized across hospitals, pathology labs, and specialty clinics to detect various types of cancer, including breast, lung, colorectal, prostate, cervical, and blood cancers. Market growth is driven by the rising global cancer burden, increasing awareness about early detection, and ongoing advancements in precision diagnostics and personalized medicine.

Market Growth Drivers:

The global cancer diagnostics market is propelled by multiple factors, notably the increasing incidence of cancer worldwide due to aging populations, lifestyle changes, and environmental factors. Early detection through advanced diagnostic technologies significantly improves survival rates, driving demand for innovative solutions. Technological advancements such as next-generation sequencing (NGS), liquid biopsy, and AI-powered diagnostic imaging are transforming cancer detection and facilitating minimally invasive approaches. Government initiatives supporting cancer screening programs, rising healthcare expenditure, and the growing adoption of companion diagnostics in oncology further stimulate market expansion.

Market Restraints:

Despite robust growth prospects, the cancer diagnostics market faces several challenges, including high diagnostic costs, especially for advanced molecular and genomic tests. Limited access to diagnostic facilities in low- and middle-income countries impedes early detection and treatment. Additionally, the complexity of cancer heterogeneity and evolving genetic mutations requires continuous innovation and clinical validation, raising development costs and time-to-market. Regulatory hurdles and reimbursement constraints also impact the commercial viability of emerging diagnostic technologies. Addressing these challenges necessitates cross-sector collaboration and targeted investment in affordable, scalable diagnostic platforms.

Market Opportunities:

The cancer diagnostics market presents significant growth opportunities driven by technological innovations and the expanding role of artificial intelligence and machine learning in diagnostics. The emergence of liquid biopsy as a non-invasive, real-time cancer monitoring tool is gaining traction. Growing investments in biomarker discovery, integration of big data analytics, and the development of multiplex diagnostic platforms open new avenues for personalized and early-stage cancer diagnostics. Moreover, increased focus on home-based cancer screening tools and mobile diagnostics can improve accessibility and compliance, especially in remote or underserved areas.

Key Questions Answered in the Report:

  • What are the key factors contributing to the global growth of the cancer diagnostics market?
  • Which diagnostic technologies and cancer types are driving market demand across various regions?
  • How are innovations in molecular diagnostics and AI reshaping the competitive dynamics of the market?
  • Who are the leading players in the cancer diagnostics market, and what strategies are they adopting for market leadership?
  • What are the emerging trends and future opportunities in the global cancer diagnostics landscape?

Competitive Intelligence and Business Strategy:

Leading players in the global cancer diagnostics market, such as F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, and Becton, Dickinson and Company, are actively investing in R&D, strategic collaborations, and acquisitions to enhance their diagnostic portfolios. These companies focus on developing comprehensive cancer detection platforms combining genetic, proteomic, and imaging-based technologies. Collaborations with pharmaceutical firms for companion diagnostics and personalized treatment regimens are key strategic moves. In addition, companies are expanding their geographic presence through partnerships with local healthcare providers and governments to address the rising demand for cancer diagnostics across emerging markets.

Key Companies Profiled:

  • F. Hoffmann-La Roche Ltd
  • Thermo Fisher Scientific Inc.
  • Abbott Laboratories
  • Illumina Inc.
  • bioMerieux SA
  • Qiagen
  • Siemens Healthineers
  • GE Healthcare
  • Hologic Inc.
  • Koninklijke Philips N.V. (Philips)
  • Agilent Technologies Inc.
  • Becton, Dickinson and Company (BD)
  • Myriad Genetics Inc.
  • AstraZeneca
  • Regeneron
  • Novartis
  • Bio-Rad Laboratories
  • Cancer Diagnostics Inc.
  • Quidel Corporation
  • Others

Market Segmentation

By Diagnostic Test

  • Biomarker Test
  • Prostate-Specific Antigen (PSA)
  • Circulating Tumor Cells (CTC)
  • Alpha-Fetoprotein (AFP)
  • Cancer Antigen 125 (CA-125)
  • HER2
  • Other
  • Imaging Technology
  • Magnetic Resonance Imaging (MRI)
  • Computed Tomography (CT)
  • Positron Emission Tomography (PET)
  • Mammography
  • Others
  • Endoscopy
  • Colonoscopy
  • Biopsy
  • Others

By Application

  • Breast Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Melanoma Cancer
  • Blood Cancer
  • Ovarian Cancer
  • Other

By End-Use

  • Hospitals
  • Diagnostic Laboratories
  • Cancer Research Institutes
  • Ambulatory Surgical Centers

By Region

  • North America
  • Europe
  • East Asia
  • South Asia and Oceania
  • Latin America
  • Middle East and Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Cancer Diagnostics Market Snapshot, 2025-2032
  • 1.2. Market Opportunity Assessment, 2025-2032, US$ Bn
  • 1.3. Key Market Trends
  • 1.4. Future Market Projections
  • 1.5. Premium Market Insights
  • 1.6. Industry Developments and Key Market Events
  • 1.7. PMR Analysis and Recommendations

2. Market Overview

  • 2.1. Market Scope and Definition
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Opportunity
    • 2.2.4. Challenges
    • 2.2.5. Key Trends
  • 2.3. COVID-19 Impact Analysis
  • 2.4. Forecast Factors - Relevance and Impact

3. Value Added Insights

  • 3.1. Value Chain Analysis
  • 3.2. Diagnostic Test Adoption / Usage Analysis
  • 3.3. Prevalence & Incidence of Cancer
  • 3.4. Government Initiatives & Funding in Cancer Diagnostics
  • 3.5. Key Market Players
  • 3.6. Regulatory Landscape
  • 3.7. PESTLE Analysis
  • 3.8. Porter's Five Force Analysis
  • 3.9. Consumer Behavior Analysis

4. Global Cancer Diagnostics Market Outlook

  • 4.1. Key Highlights
    • 4.1.1. Market Size (US$ Bn) and Y-o-Y Growth
    • 4.1.2. Absolute $ Opportunity
  • 4.2. Market Size (US$ Bn) Analysis and Forecast
    • 4.2.1. Historical Market Size (US$ Bn) Analysis, 2019-2024
    • 4.2.2. Current Market Size (US$ Bn) Analysis and Forecast, 2025-2032
  • 4.3. Global Cancer Diagnostics Market Outlook Diagnostic Test
    • 4.3.1. Historical Market Size (US$ Bn) Analysis, By Diagnostic Test, 2019-2024
    • 4.3.2. Current Market Size (US$ Bn) Analysis and Forecast, By Diagnostic Test, 2025-2032
      • 4.3.2.1. Biomarker Test
        • 4.3.2.1.1. Prostate-Specific Antigen (PSA)
        • 4.3.2.1.2. Circulating Tumor Cells (CTC)
        • 4.3.2.1.3. Alpha-Fetoprotein (AFP)
        • 4.3.2.1.4. Cancer Antigen 125 (CA-125)
        • 4.3.2.1.5. HER2
        • 4.3.2.1.6. Other
      • 4.3.2.2. Imaging Technology
        • 4.3.2.2.1. Magnetic Resonance Imaging (MRI)
        • 4.3.2.2.2. Computed Tomography (CT)
        • 4.3.2.2.3. Positron Emission Tomography (PET)
        • 4.3.2.2.4. Mammography
        • 4.3.2.2.5. Others
      • 4.3.2.3. Endoscopy
      • 4.3.2.4. Colonoscopy
      • 4.3.2.5. Biopsy
      • 4.3.2.6. Others
    • 4.3.3. Market Attractiveness Analysis: Diagnostic Test
  • 4.4. Global Cancer Diagnostics Market Outlook Form
    • 4.4.1. Historical Market Size (US$ Bn) Analysis, By Form, 2019-2024
    • 4.4.2. Current Market Size (US$ Bn) Analysis and Forecast, By Form, 2025-2032
      • 4.4.2.1. Isolates
      • 4.4.2.2. Concentrates
      • 4.4.2.3. Hydrolysates
    • 4.4.3. Market Attractiveness Analysis: Form
  • 4.5. Global Cancer Diagnostics Market Outlook Application
    • 4.5.1. Historical Market Size (US$ Bn) Analysis, By Application, 2019-2024
    • 4.5.2. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
      • 4.5.2.1. Lung Cancer
      • 4.5.2.2. Breast Cancer
      • 4.5.2.3. Prostate Cancer
      • 4.5.2.4. Colorectal Cancer
      • 4.5.2.5. Melanoma Cancer
      • 4.5.2.6. Blood Cancer
      • 4.5.2.7. Ovarian Cancer
      • 4.5.2.8. Other
    • 4.5.3. Market Attractiveness Analysis: Application
  • 4.6. Global Cancer Diagnostics Market Outlook End-use
    • 4.6.1. Historical Market Size (US$ Bn) Analysis, By End-use, 2019-2024
    • 4.6.2. Current Market Size (US$ Bn) Analysis and Forecast, By End-use, 2025-2032
      • 4.6.2.1. Hospitals
      • 4.6.2.2. Diagnostic Laboratories
      • 4.6.2.3. Cancer Research Institutes
      • 4.6.2.4. Ambulatory Surgical Centers
    • 4.6.3. Market Attractiveness Analysis: End-use

5. Global Cancer Diagnostics Market Outlook Region

  • 5.1. Historical Market Size (US$ Bn) Analysis, By Region, 2019-2024
  • 5.2. Current Market Size (US$ Bn) Analysis and Forecast, By Region, 2025-2032
    • 5.2.1. North America
    • 5.2.2. Latin America
    • 5.2.3. Europe
    • 5.2.4. East Asia
    • 5.2.5. South Asia and Oceania
    • 5.2.6. Middle East & Africa
  • 5.3. Market Attractiveness Analysis: Region

6. North America Cancer Diagnostics Market Outlook

  • 6.1. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 6.1.1. By Country
    • 6.1.2. By Diagnostic Test
    • 6.1.3. By Application
    • 6.1.4. By End-use
  • 6.2. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 6.2.1. U.S.
    • 6.2.2. Canada
  • 6.3. Current Market Size (US$ Bn) Analysis and Forecast, By Diagnostic Test, 2025-2032
    • 6.3.1. Biomarker Test
      • 6.3.1.1. Prostate-Specific Antigen (PSA)
      • 6.3.1.2. Circulating Tumor Cells (CTC)
      • 6.3.1.3. Alpha-Fetoprotein (AFP)
      • 6.3.1.4. Cancer Antigen 125 (CA-125)
      • 6.3.1.5. HER2
      • 6.3.1.6. Other
    • 6.3.2. Imaging Technology
      • 6.3.2.1. Magnetic Resonance Imaging (MRI)
      • 6.3.2.2. Computed Tomography (CT)
      • 6.3.2.3. Positron Emission Tomography (PET)
      • 6.3.2.4. Mammography
      • 6.3.2.5. Others
    • 6.3.3. Endoscopy
    • 6.3.4. Colonoscopy
    • 6.3.5. Biopsy
    • 6.3.6. Others
  • 6.4. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
    • 6.4.1. Lung Cancer
    • 6.4.2. Breast Cancer
    • 6.4.3. Prostate Cancer
    • 6.4.4. Colorectal Cancer
    • 6.4.5. Melanoma Cancer
    • 6.4.6. Blood Cancer
    • 6.4.7. Ovarian Cancer
    • 6.4.8. Other
  • 6.5. Current Market Size (US$ Bn) Analysis and Forecast, By End-use, 2025-2032
    • 6.5.1. Hospitals
    • 6.5.2. Diagnostic Laboratories
    • 6.5.3. Cancer Research Institutes
    • 6.5.4. Ambulatory Surgical Centers
  • 6.6. Market Attractiveness Analysis

7. Europe Cancer Diagnostics Market Outlook

  • 7.1. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 7.1.1. By Country
    • 7.1.2. By Diagnostic Test
    • 7.1.3. By Form
    • 7.1.4. By Application
    • 7.1.5. By End-use
  • 7.2. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 7.2.1. Germany
    • 7.2.2. France
    • 7.2.3. U.K.
    • 7.2.4. Italy
    • 7.2.5. Spain
    • 7.2.6. Russia
    • 7.2.7. Rest of Europe
  • 7.3. Current Market Size (US$ Bn) Analysis and Forecast, By Diagnostic Test, 2025-2032
    • 7.3.1. Biomarker Test
      • 7.3.1.1. Prostate-Specific Antigen (PSA)
      • 7.3.1.2. Circulating Tumor Cells (CTC)
      • 7.3.1.3. Alpha-Fetoprotein (AFP)
      • 7.3.1.4. Cancer Antigen 125 (CA-125)
      • 7.3.1.5. HER2
      • 7.3.1.6. Other
    • 7.3.2. Imaging Technology
      • 7.3.2.1. Magnetic Resonance Imaging (MRI)
      • 7.3.2.2. Computed Tomography (CT)
      • 7.3.2.3. Positron Emission Tomography (PET)
      • 7.3.2.4. Mammography
      • 7.3.2.5. Others
    • 7.3.3. Endoscopy
    • 7.3.4. Colonoscopy
    • 7.3.5. Biopsy
    • 7.3.6. Others
  • 7.4. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
    • 7.4.1. Lung Cancer
    • 7.4.2. Breast Cancer
    • 7.4.3. Prostate Cancer
    • 7.4.4. Colorectal Cancer
    • 7.4.5. Melanoma Cancer
    • 7.4.6. Blood Cancer
    • 7.4.7. Ovarian Cancer
    • 7.4.8. Other
  • 7.5. Current Market Size (US$ Bn) Analysis and Forecast, By End-use, 2025-2032
    • 7.5.1. Hospitals
    • 7.5.2. Diagnostic Laboratories
    • 7.5.3. Cancer Research Institutes
    • 7.5.4. Ambulatory Surgical Centers
  • 7.6. Market Attractiveness Analysis

8. East Asia Cancer Diagnostics Market Outlook

  • 8.1. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 8.1.1. By Country
    • 8.1.2. By Diagnostic Test
    • 8.1.3. By Application
    • 8.1.4. By End-use
  • 8.2. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 8.2.1. China
    • 8.2.2. Japan
    • 8.2.3. South Korea
  • 8.3. Current Market Size (US$ Bn) Analysis and Forecast, By Diagnostic Test, 2025-2032
    • 8.3.1. Biomarker Test
      • 8.3.1.1. Prostate-Specific Antigen (PSA)
      • 8.3.1.2. Circulating Tumor Cells (CTC)
      • 8.3.1.3. Alpha-Fetoprotein (AFP)
      • 8.3.1.4. Cancer Antigen 125 (CA-125)
      • 8.3.1.5. HER2
      • 8.3.1.6. Other
    • 8.3.2. Imaging Technology
      • 8.3.2.1. Magnetic Resonance Imaging (MRI)
      • 8.3.2.2. Computed Tomography (CT)
      • 8.3.2.3. Positron Emission Tomography (PET)
      • 8.3.2.4. Mammography
      • 8.3.2.5. Others
    • 8.3.3. Endoscopy
    • 8.3.4. Colonoscopy
    • 8.3.5. Biopsy
    • 8.3.6. Others
  • 8.4. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
    • 8.4.1. Lung Cancer
    • 8.4.2. Breast Cancer
    • 8.4.3. Prostate Cancer
    • 8.4.4. Colorectal Cancer
    • 8.4.5. Melanoma Cancer
    • 8.4.6. Blood Cancer
    • 8.4.7. Ovarian Cancer
    • 8.4.8. Other
  • 8.5. Current Market Size (US$ Bn) Analysis and Forecast, By End-use, 2025-2032
    • 8.5.1. Hospitals
    • 8.5.2. Diagnostic Laboratories
    • 8.5.3. Cancer Research Institutes
    • 8.5.4. Ambulatory Surgical Centers
  • 8.6. Market Attractiveness Analysis

9. South Asia & Oceania Cancer Diagnostics Market Outlook

  • 9.1. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 9.1.1. By Country
    • 9.1.2. By Diagnostic Test
    • 9.1.3. By Application
    • 9.1.4. By End-use
  • 9.2. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 9.2.1. India
    • 9.2.2. Indonesia
    • 9.2.3. Thailand
    • 9.2.4. Singapore
    • 9.2.5. ANZ
    • 9.2.6. Rest of South Asia & Oceania
  • 9.3. Current Market Size (US$ Bn) Analysis and Forecast, By Diagnostic Test, 2025-2032
    • 9.3.1. Biomarker Test
      • 9.3.1.1. Prostate-Specific Antigen (PSA)
      • 9.3.1.2. Circulating Tumor Cells (CTC)
      • 9.3.1.3. Alpha-Fetoprotein (AFP)
      • 9.3.1.4. Cancer Antigen 125 (CA-125)
      • 9.3.1.5. HER2
      • 9.3.1.6. Other
    • 9.3.2. Imaging Technology
      • 9.3.2.1. Magnetic Resonance Imaging (MRI)
      • 9.3.2.2. Computed Tomography (CT)
      • 9.3.2.3. Positron Emission Tomography (PET)
      • 9.3.2.4. Mammography
      • 9.3.2.5. Others
    • 9.3.3. Endoscopy
    • 9.3.4. Colonoscopy
    • 9.3.5. Biopsy
    • 9.3.6. Others
  • 9.4. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
    • 9.4.1. Lung Cancer
    • 9.4.2. Breast Cancer
    • 9.4.3. Prostate Cancer
    • 9.4.4. Colorectal Cancer
    • 9.4.5. Melanoma Cancer
    • 9.4.6. Blood Cancer
    • 9.4.7. Ovarian Cancer
    • 9.4.8. Other
  • 9.5. Current Market Size (US$ Bn) Analysis and Forecast, By End-use, 2025-2032
    • 9.5.1. Hospitals
    • 9.5.2. Diagnostic Laboratories
    • 9.5.3. Cancer Research Institutes
    • 9.5.4. Ambulatory Surgical Centers
  • 9.6. Market Attractiveness Analysis

10. Latin America Cancer Diagnostics Market Outlook

  • 10.1. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 10.1.1. By Country
    • 10.1.2. By Diagnostic Test
    • 10.1.3. By Application
    • 10.1.4. By End-use
  • 10.2. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 10.2.1. Brazil
    • 10.2.2. Mexico
    • 10.2.3. Rest of Latin America
  • 10.3. Current Market Size (US$ Bn) Analysis and Forecast, By Diagnostic Test, 2025-2032
    • 10.3.1. Biomarker Test
      • 10.3.1.1. Prostate-Specific Antigen (PSA)
      • 10.3.1.2. Circulating Tumor Cells (CTC)
      • 10.3.1.3. Alpha-Fetoprotein (AFP)
      • 10.3.1.4. Cancer Antigen 125 (CA-125)
      • 10.3.1.5. HER2
      • 10.3.1.6. Other
    • 10.3.2. Imaging Technology
      • 10.3.2.1. Magnetic Resonance Imaging (MRI)
      • 10.3.2.2. Computed Tomography (CT)
      • 10.3.2.3. Positron Emission Tomography (PET)
      • 10.3.2.4. Mammography
      • 10.3.2.5. Others
    • 10.3.3. Endoscopy
    • 10.3.4. Colonoscopy
    • 10.3.5. Biopsy
    • 10.3.6. Others
  • 10.4. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
    • 10.4.1. Lung Cancer
    • 10.4.2. Breast Cancer
    • 10.4.3. Prostate Cancer
    • 10.4.4. Colorectal Cancer
    • 10.4.5. Melanoma Cancer
    • 10.4.6. Blood Cancer
    • 10.4.7. Ovarian Cancer
    • 10.4.8. Other
  • 10.5. Current Market Size (US$ Bn) Analysis and Forecast, By End-use, 2025-2032
    • 10.5.1. Hospitals
    • 10.5.2. Diagnostic Laboratories
    • 10.5.3. Cancer Research Institutes
    • 10.5.4. Ambulatory Surgical Centers
  • 10.6. Market Attractiveness Analysis

11. Middle East & Africa Cancer Diagnostics Market Outlook

  • 11.1. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 11.1.1. By Country
    • 11.1.2. By Diagnostic Test
    • 11.1.3. By Application
    • 11.1.4. By End-use
  • 11.2. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 11.2.1. GCC Countries
    • 11.2.2. Egypt
    • 11.2.3. South Africa
    • 11.2.4. Northern Africa
    • 11.2.5. Rest of Middle East & Africa
  • 11.3. Current Market Size (US$ Bn) Analysis and Forecast, By Diagnostic Test, 2025-2032
    • 11.3.1. Biomarker Test
      • 11.3.1.1. Prostate-Specific Antigen (PSA)
      • 11.3.1.2. Circulating Tumor Cells (CTC)
      • 11.3.1.3. Alpha-Fetoprotein (AFP)
      • 11.3.1.4. Cancer Antigen 125 (CA-125)
      • 11.3.1.5. HER2
      • 11.3.1.6. Other
    • 11.3.2. Imaging Technology
      • 11.3.2.1. Magnetic Resonance Imaging (MRI)
      • 11.3.2.2. Computed Tomography (CT)
      • 11.3.2.3. Positron Emission Tomography (PET)
      • 11.3.2.4. Mammography
      • 11.3.2.5. Others
    • 11.3.3. Endoscopy
    • 11.3.4. Colonoscopy
    • 11.3.5. Biopsy
    • 11.3.6. Others
  • 11.4. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
    • 11.4.1. Lung Cancer
    • 11.4.2. Breast Cancer
    • 11.4.3. Prostate Cancer
    • 11.4.4. Colorectal Cancer
    • 11.4.5. Melanoma Cancer
    • 11.4.6. Blood Cancer
    • 11.4.7. Ovarian Cancer
    • 11.4.8. Other
  • 11.5. Current Market Size (US$ Bn) Analysis and Forecast, By End-use, 2025-2032
    • 11.5.1. Hospitals
    • 11.5.2. Diagnostic Laboratories
    • 11.5.3. Cancer Research Institutes
    • 11.5.4. Ambulatory Surgical Centers
  • 11.6. Market Attractiveness Analysis

12. Competition Landscape

  • 12.1. Market Share Analysis, 2025
  • 12.2. Market Structure
    • 12.2.1. Competition Intensity Mapping by Market
    • 12.2.2. Competition Dashboard
  • 12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
    • 12.3.1. F. Hoffmann-La Roche Ltd
      • 12.3.1.1. Overview
      • 12.3.1.2. Segments and Sources
      • 12.3.1.3. Key Financials
      • 12.3.1.4. Market Developments
      • 12.3.1.5. Market Strategy
    • 12.3.2. Thermo Fisher Scientific Inc.
    • 12.3.3. Abbott Laboratories
    • 12.3.4. Illumina Inc.
    • 12.3.5. bioMerieux SA
    • 12.3.6. Qiagen
    • 12.3.7. Siemens Healthineers
    • 12.3.8. GE Healthcare
    • 12.3.9. Hologic Inc.
    • 12.3.10. Agilent Technologies Inc.
    • 12.3.11. Becton, Dickinson and Company (BD)
    • 12.3.12. Myriad Genetics Inc.
    • 12.3.13. AstraZeneca
    • 12.3.14. Regeneron
    • 12.3.15. Novartis
    • 12.3.16. BIO-RAD LABORATORIES
    • 12.3.17. CANCER DIAGNOSTICS INC.
    • 12.3.18. QUIDEL CORPORATION
    • 12.3.19. Koninklijke Philips N.V. (Philips)
    • 12.3.20. Others

13. Appendix

  • 13.1. Research Methodology
  • 13.2. Research Assumptions
  • 13.3. Acronyms and Abbreviations